title: RAS's cloak of invincibility slips at last?
abstract: KRAS is the most frequently activated oncogene in human cancer, but it has, so far, shrugged off all attempts to inhibit its function directly. However, a recent report provides an entirely new approach to blocking mutant KRAS with small molecules and has the added benefit of sparing the wild-type protein.
authors.affiliation: Cancer Research UK London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK. Electronic address: julian.downward@cancer.org.uk.
authors.forename: Julian
authors.initials: J
authors.lastname: Downward